ECSP045017A - Cristales de derivado de hidroxinorefedrina - Google Patents

Cristales de derivado de hidroxinorefedrina

Info

Publication number
ECSP045017A
ECSP045017A EC2004005017A ECSP045017A ECSP045017A EC SP045017 A ECSP045017 A EC SP045017A EC 2004005017 A EC2004005017 A EC 2004005017A EC SP045017 A ECSP045017 A EC SP045017A EC SP045017 A ECSP045017 A EC SP045017A
Authority
EC
Ecuador
Prior art keywords
hydroxinorefedrine
derivative crystals
ethyl
polaquiuria
dimethylphenoxy
Prior art date
Application number
EC2004005017A
Other languages
English (en)
Inventor
Isawa Hidetoshi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of ECSP045017A publication Critical patent/ECSP045017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invención proporciona hidrocloruro de (-)-2-[4-[2-[[(1S,2R)-2-hidroxi-2-(4-hidroxifenil)-1-metiletil]amino]etil]-2,5-dimetilfenoxi]acetato de etilo, formas cristalinas del mismo y composiciones farmacéuticas que los contienen, que tienen excelentes efectos estimulantes de ß3-adrenoceptor, efectos terapéuticos sobre polaquiuria o incontinencia urinaria y estabilidades en el almacenamiento y son útiles como medicamento
EC2004005017A 2001-09-13 2004-03-12 Cristales de derivado de hidroxinorefedrina ECSP045017A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13

Publications (1)

Publication Number Publication Date
ECSP045017A true ECSP045017A (es) 2004-09-27

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005017A ECSP045017A (es) 2001-09-13 2004-03-12 Cristales de derivado de hidroxinorefedrina

Country Status (29)

Country Link
US (1) US7208520B2 (es)
EP (1) EP1426355B1 (es)
JP (1) JP4157036B2 (es)
KR (2) KR20080098691A (es)
CN (1) CN1275936C (es)
AT (1) ATE411276T1 (es)
AU (1) AU2002330453B2 (es)
BR (1) BR0212494A (es)
CA (1) CA2458544C (es)
CO (1) CO5560555A2 (es)
CY (1) CY1109409T1 (es)
DE (1) DE60229404D1 (es)
DK (1) DK1426355T3 (es)
EA (1) EA006022B1 (es)
EC (1) ECSP045017A (es)
ES (1) ES2314092T3 (es)
HK (1) HK1070051A1 (es)
HR (1) HRP20040250A2 (es)
HU (1) HUP0401694A3 (es)
IL (2) IL160681A0 (es)
MX (1) MXPA04002449A (es)
NO (1) NO328252B1 (es)
NZ (1) NZ531602A (es)
PL (1) PL206246B1 (es)
PT (1) PT1426355E (es)
SI (1) SI1426355T1 (es)
UA (1) UA77000C2 (es)
WO (1) WO2003024916A1 (es)
ZA (1) ZA200401757B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
SI1620085T1 (sl) * 2003-05-05 2008-12-31 Kissei Pharmaceutical Uporaba derivatov fenoksiocetne kisline za zdravljenje hiperaktivnega sečnega mehurja
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
AU2004285289A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
CA2585037A1 (en) 2004-10-26 2006-05-04 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
TWI356699B (en) 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
WO2006123517A1 (ja) * 2005-04-26 2006-11-23 Kissei Pharmaceutical Co., Ltd. ヒドロキシノルエフェドリン誘導体塩酸塩の結晶多形
EP1878718A4 (en) * 2005-04-26 2010-07-28 Kissei Pharmaceutical CRYSTAL OF A HYDROXYNOREPHEDRINE DERIVATIVY HYDROCHLORIDE 1/4 HYDRATE
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP2296686B2 (en) 2008-05-21 2017-11-01 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形

Also Published As

Publication number Publication date
PL367874A1 (en) 2005-03-07
US7208520B2 (en) 2007-04-24
EP1426355A4 (en) 2006-03-29
CN1275936C (zh) 2006-09-20
HK1070051A1 (en) 2005-06-10
ES2314092T3 (es) 2009-03-16
CN1553890A (zh) 2004-12-08
MXPA04002449A (es) 2004-07-23
ATE411276T1 (de) 2008-10-15
HRP20040250A2 (en) 2005-02-28
ZA200401757B (en) 2005-03-03
CO5560555A2 (es) 2005-09-30
KR100874952B1 (ko) 2008-12-19
CY1109409T1 (el) 2014-07-02
EA200400311A1 (ru) 2004-08-26
DE60229404D1 (de) 2008-11-27
PL206246B1 (pl) 2010-07-30
HUP0401694A3 (en) 2008-03-28
NZ531602A (en) 2006-01-27
IL160681A0 (en) 2004-08-31
EA006022B1 (ru) 2005-08-25
CA2458544C (en) 2010-08-17
PT1426355E (pt) 2008-11-03
HUP0401694A2 (hu) 2004-11-29
IL160681A (en) 2010-06-16
EP1426355B1 (en) 2008-10-15
NO20041060L (no) 2004-06-11
AU2002330453B2 (en) 2008-04-17
US20040242686A1 (en) 2004-12-02
WO2003024916A1 (fr) 2003-03-27
KR20080098691A (ko) 2008-11-11
EP1426355A1 (en) 2004-06-09
JPWO2003024916A1 (ja) 2004-12-24
UA77000C2 (en) 2006-10-16
KR20040044881A (ko) 2004-05-31
CA2458544A1 (en) 2003-03-27
JP4157036B2 (ja) 2008-09-24
DK1426355T3 (da) 2009-02-23
NO328252B1 (no) 2010-01-18
SI1426355T1 (sl) 2009-02-28
BR0212494A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
ECSP045017A (es) Cristales de derivado de hidroxinorefedrina
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
UY27592A1 (es) Nuevo uso
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE386725T1 (de) Heterocyclylverbindungen
SE0402925D0 (sv) Novel Compounds
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR029412A1 (es) Forma cristalina
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
UY29133A1 (es) Amidas conteniendo (!!2-tert-butil-1-(tetrahidro-2h-piran-4-ilmetil)-1h-bencimidazol-5-!!) (metil)amino!sulfonilo) como sustituyente. procedimiento de preparacion, composiciones que lo contienen y aplicaciones
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
AR033779A1 (es) Compuestos utiles en la enfermedad de reflujo
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
ATE295845T1 (de) Prucaloprid-n-oxid
AR045248A1 (es) Oxazoles, su fabricacion y uso como agentes farmaceuticos
DK1652836T3 (da) Aminosyrediamider i non-alfa-stilling, som egner sig som adjuvanser til administration af aktrive biologiske midler
AR034648A1 (es) Forma cristalina de una feniletanolamina, su preparacion y composiciones farmaceuticas que la contienen